The Texas Heart Institute (THI) and BiVACOR, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) on July 9, 2024.
Study explores the role of sex on mRNA and protein levels and its genetic regulation in brain
Researchers investigated the impact of biological sex on protein levels and its genomic control by analyzing 1,277 proteomes of the brain.